A network approach to developing immuno-oncology combinations in Canada

Immune checkpoint inhibitors have revolutionized care for many cancer indications, with considerable effort now being focused on increasing the rate, depth, and duration of patient response. One strategy is to combine immune strategies (for example, ctla-4 and PD-1/L1–directed agents) to harness add...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Curr Oncol
Asıl Yazarlar: Higenell, V., Fajzel, R., Batist, G., Cheema, P.K., McArthur, H.L., Melosky, B., Morris, D., Petrella, T.M., Sangha, R., Savard, M.F., Sridhar, S.S., Stagg, J., Stewart, D.J., Verma, S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Multimed Inc. 2019
Konular:
Practice Guideline
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6476440/
https://ncbi.nlm.nih.gov/pubmed/31043804
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.26.4393
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller